KeytoLead

Bridging the Gap in Drug Discovery. KeytoLead is a Swedish Partner Research Organisation (PRO) that focuses on pre-clinical pharmaceutical research in the lead generation phase. Innovative therapeutic approaches originating in academia are being developed to a stage where the programs have gained significant value for the life science industry. The long track record of successful Lead Generation deliveries gained from the pharmaceutical industry provides you with direct access to world-class experience in Lead Generation. KeytoLead has expertise in all aspects of lead generation, such as compound selection, iterative screens, fragment based lead generation (FBLG), HTS evaluation (clustering, scoring and actives selection), development of clusters into lead series (expansion via compound libraries, scaffold hopping and multi-parameter optimisation), management of secondary screens (physical properties, ADMET), project management and presentation for customers or scientific committees. Synthetic organic chemistry is an important area of lead generation which is why both single compound synthesis and compound library synthesis are integrated parts of KeytoLead. The KeytoLead team has extensive experience in compound library generation from AstraZeneca’s Compound Collection Enhancement (CCE) initiative during the last 10 years.